Home > Cardiology > NOACs an alternative to LMWHs for cancer-related thromboembolism in Asians

NOACs an alternative to LMWHs for cancer-related thromboembolism in Asians

Journal
JAMA Network Open
Reuters Health - 12/02/2021 - Non-vitamin K antagonist oral anticoagulants (NOACs) appear to be at least as safe and effective as low-molecular-weight heparins (LMWHs) in Asians with cancer and acute venous thromboembolism (VTE), new research suggests. As Dr. Wen-Kuan Huang told Reuters Health by email, "NOACs could be a better alternative to LMWHs for treating Asian individuals with cancer-associated VTE. Our study demonstrated that NOACs had similar efficacy but lower gastrointestinal bleeding risk compared with LMWHs." After their introduction more than a decade ago, NOACs have proved more effective than warfarin in clinical practice for patients with acute VTE, Dr. Huang, of Chang Gung University College of Medicine, in Taoyuan, Taiwan, and colleagues note in JAMA Network Open. However, they add, it remained uncertain "whether superior clinical benefits were associated with NOACs compared with LMWHs regarding acute VTE in patients with cancer, who have hi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on